Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.

Boussen, Inès; Salmona, Maud; Sicre De Fontbrune, Flore; Xhaard, Aliénor; De Castro, Nathalie; Delaugerre, Constance; Chaix, Marie-Laure; Molina, Jean-Michel

Boussen, Inès; Salmona, Maud; Sicre De Fontbrune, Flore; Xhaard, Aliénor; De Castro, Nathalie; Delaugerre, Constance; Chaix, Marie-Laure; Molina, Jean-Michel.

Afiliação

Boussen I; Department of Infectious Diseases, Saint Louis and Lariboisière Hospitals, APHP, Paris, France.
Salmona M; Virology Department, Saint Louis Hospital, Paris, France.
Sicre De Fontbrune F; INSERM U976, INSIGHT team, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Xhaard A; Hematology and Transplantation Department, Saint Louis Hospital, Paris, France.
De Castro N; Hematology and Transplantation Department, Saint Louis Hospital, Paris, France.
Delaugerre C; Department of Infectious Diseases, Saint Louis and Lariboisière Hospitals, APHP, Paris, France.
Chaix ML; Virology Department, Saint Louis Hospital, Paris, France.
Molina JM; INSERM U944, Institut de Recherche Saint Louis, Université de Paris, Paris, France.

Antivir Ther ; 29(1): 13596535221097495, 2024 02.

Article em En | MEDLINE | ID: mdl-38353416

ABSTRACT

ABSTRACT

We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

Assuntos

Anticorpos Monoclonais Humanizados; COVID-19; Infecção Hospitalar; Transplante de Células-Tronco Hematopoéticas; Humanos; Infecção Hospitalar/tratamento farmacológico; COVID-19/diagnóstico; SARS-CoV-2; Anticorpos Neutralizantes; Mutação; Transplante de Células-Tronco; Transplante de Células-Tronco Hematopoéticas/efeitos adversos

Palavras-chave

allogeneic stem cell transplant recipient; bamlanivimab; immune escape; mutation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecção Hospitalar / Transplante de Células-Tronco Hematopoéticas / Anticorpos Monoclonais Humanizados / COVID-19 Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google